NFE2L2 and myelodysplastic syndrome: Moreover, MDS patients that respond to ESA treatment showed higher expression levels of the NFE2L2 gene (Med: 4.544, IqR: 6.150; p = 0.001) than those that did not respond to ESA treatment (Med: 1.945, IqR: 2.590; Figure 2).